Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2018 Oct 7

PMID 30291106

Citations 1058

Authors

Melanie J Davies

David A DAlessio

Judith Fradkin

Walter N Kernan

Chantal Mathieu

Geltrude Mingrone

Peter Rossing

Apostolos Tsapas

Deborah J Wexler

John B Buse

Affiliations

Soon will be listed here.

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Citing Articles

Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.

Rasouli N, Wilding J, Kwan A, Paik J, Sharma P, Peleshok J Diabetes Ther. 2025; .

PMID: 40016573 DOI: 10.1007/s13300-025-01711-0.

Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study.

Sansone D, Garino F, Gottero C, Gauna C, Clerico A, Corneli G Acta Diabetol. 2025; .

PMID: 40014091 DOI: 10.1007/s00592-025-02475-6.

Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?.

Al-Awadi A, Gray S, Al-Ozairi E Rev Endocr Metab Disord. 2025; .

PMID: 39998784 DOI: 10.1007/s11154-025-09947-8.

Efficacy and safety of red ginseng extract powder (KGC05pg) in achieving glycemic control in prediabetic Korean adults: A 12-week, single-center, randomized, double-blind, parallel-group, placebo-controlled study.

Jeong Y, Lee S, Shim S, Jang K, Kim J Medicine (Baltimore). 2025; 103(52):e41130.

PMID: 39969290 PMC: 11688016. DOI: 10.1097/MD.0000000000041130.

A Case of Intussusception With Bowel Obstruction in a Gastric Roux-en-Y Patient Prescribed Semaglutide.

Pavuluri S, Toumar A, Duffy A J Am Coll Emerg Physicians Open. 2025; 6(2):100045.

PMID: 39959551 PMC: 11830288. DOI: 10.1016/j.acepjo.2025.100045.

References

Einhorn D, Rendell M, Rosenzweig J, EGAN J, Mathisen A, Schneider R . Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2001; 22(12):1395-409. DOI: 10.1016/s0149-2918(00)83039-8. View

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A . Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(9):2255-2263. DOI: 10.1111/dom.13361. View

Khunti K, Kosiborod M, Ray K . Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. Diabetes Obes Metab. 2018; 20(6):1337-1341. DOI: 10.1111/dom.13243. View

Breslin M, Mullan R, Montori V . The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008; 73(3):465-72. DOI: 10.1016/j.pec.2008.07.024. View

Murphy M, Byrne M, Galvin R, Boland F, Fahey T, Smith S . Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings. BMJ Open. 2017; 7(8):e015135. PMC: 5724222. DOI: 10.1136/bmjopen-2016-015135. View

Khunti K, Chatterjee S, Gerstein H, Zoungas S, Davies M . Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol. 2018; 6(10):821-832. DOI: 10.1016/S2213-8587(18)30025-1. View

Mishriky B, Cummings D, Tanenberg R . The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015; 109(2):378-88. DOI: 10.1016/j.diabres.2015.05.025. View

Mahaffey K, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J . Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013; 166(2):240-249.e1. DOI: 10.1016/j.ahj.2013.05.004. View

10.

Chudyk A, Petrella R . Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34(5):1228-37. PMC: 3114506. DOI: 10.2337/dc10-1881. View

11.

Gangji A, Cukierman T, Gerstein H, Goldsmith C, Clase C . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389-94. DOI: 10.2337/dc06-1789. View

12.

Giugliano D, Chiodini P, Maiorino M, Bellastella G, Esposito K . Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2015; 51(3):417-28. DOI: 10.1007/s12020-015-0718-3. View

13.

Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A . Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014; 311(22):2297-304. DOI: 10.1001/jama.2014.5988. View

14.

Li Z, Zhang Y, Quan X, Yang Z, Zeng X, Ji L . Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS One. 2016; 11(5):e0154206. PMC: 4861281. DOI: 10.1371/journal.pone.0154206. View

15.

Foroutan N, Muratov S, Levine M . Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Clin Invest Med. 2016; 39(2):E48-62. DOI: 10.25011/cim.v39i2.26481. View

16.

Rodbard H, Visco V, Andersen H, Hiort L, Shu D . Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014; 2(1):30-7. DOI: 10.1016/S2213-8587(13)70090-1. View

17.

Del Prato S, Camisasca R, Wilson C, Fleck P . Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014; 16(12):1239-46. DOI: 10.1111/dom.12377. View

18.

Conason A, Teixeira J, Hsu C, Puma L, Knafo D, Geliebter A . Substance use following bariatric weight loss surgery. JAMA Surg. 2013; 148(2):145-50. DOI: 10.1001/2013.jamasurg.265. View

19.

Maruthur N, Tseng E, Hutfless S, Wilson L, Suarez-Cuervo C, Berger Z . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016; 164(11):740-51. DOI: 10.7326/M15-2650. View

20.

Imam T . Changes in metformin use in chronic kidney disease. Clin Kidney J. 2017; 10(3):301-304. PMC: 5466114. DOI: 10.1093/ckj/sfx017. View